RayKnowChina Research Map
Shortlist0

Lanzhou

Gansu Provincial Hospital

甘肃省人民医院

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Gansu Provincial Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌2 papers led
  2. Stomach cancer胃癌76 papers led
  3. Osteosarcoma骨肉瘤7 papers led
  4. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  5. Ewing sarcoma尤文肉瘤1 paper led
  6. Multiple myeloma多发性骨髓瘤3 papers led
  7. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  8. Hepatic echinococcosis肝包虫病1 paper led
  9. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  10. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  11. IgA nephropathyIgA 肾病0 papers led
  12. Congenital diaphragmatic hernia先天性膈疝1 paper led
  13. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 2 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Lanzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 76 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
76
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 6620212022: 8820222023: 191920232024: 202020242025: 20202025

3 hospitals in Lanzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  3. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  4. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIPeritoneal spread & advanced disease
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led76
  1. EBV-miR-BART14-3p Targets LACTB to Enhance Gastric Cancer Cell Proliferation and Migration.2026Biochemical genetics
  2. Optimal artificial intelligence model based on gastrointestinal filling contrast-enhanced ultrasound: Risk stratification of gastric gastrointestinal stromal tumors.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Clinical application and observation of 5G remote robotic radical gastrectomy for gastric cancer.2026Surgical endoscopy
  4. Comprehensive Analysis of Potential Common Pathogenic Mechanisms for COVID-19 Infection and Gastric Cancer.2025Analytical cellular pathology (Amsterdam)Free full text
  5. Meta-analysis of the efficacy of applying reduced surgery for the treatment of asymptomatic unresectable advanced gastric cancer.2025BMC gastroenterologyFree full text
  6. CBX2 and EZH2 cooperatively contribute to 5-Fu resistance in gastric cancer by suppressing ferroptosis via trimethylation of H3k27.2025Cellular signalling
  7. Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations.2025Combinatorial chemistry & high throughput screening
  8. Expression, Characteristics, and Clinical Target Prediction of PIK3C3/ vps34 in Gastric Cancer.2025Current cancer drug targets
  9. Downregulation of LncRNA CCAT1 Enhances Chemosensitivity in Cisplatin-Resistant Gastric Cancer Cells.2025Drug development research
  10. Robotic versus laparoscopic gastrectomy for gastric cancer in asia: A meta-analysis of short-term outcomes from six randomized controlled trials.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Spectral computed tomography-based quantitative parameters combined with extracellular volume fraction to predict lymph node metastases in gastric cancer.2025European radiology
  12. Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies.2025Frontiers in cellular and infection microbiologyFree full text
  13. Inflammatory factors collaboratively link Helicobacter pylori-induced gastritis to gastric cancer.2025Frontiers in immunologyFree full text
  14. Identification and validation VAT1 in gastric cancer through bioinformatics and experimental analysis.2025International immunopharmacology
  15. LncRNA SNHG14 Regulated by ZNF460 Promotes Gastric Cancer Progression and Metastasis by Targeting the miR-206/FNDC3A Axis.2025Journal of cellular and molecular medicineFree full text
  16. PYGO1 drives gastric cancer progression via the ITGB1/CD47 axis and is therapeutically targeted by pentagalloylglucose.2025Journal of translational medicineFree full text
  17. Construction and validation of a nomogram prediction model for the occurrence of complications in patients following robotic radical surgery for gastric cancer.2025Langenbeck's archives of surgery
  18. Correlation between dyslipidaemia and gastric cancer: pathogenesis to prevention and treatment strategies.2025Lipids in health and diseaseFree full text
  19. EBV-miR-BART5-5p regulates RORA to promote proliferation and migration of gastric cancer cells.2025PloS oneFree full text
  20. MT1JP/miR-103a-3p induce pyroptosis and regulate the tumor immune microenvironment in gastric cancer.2025Scientific reportsFree full text
  21. Targeting YBX1: A novel therapeutic strategy for gastric cancer through regulation of cellular senescence and mTOR signaling.2025Tissue & cell
  22. Challenges in clinical translation of artificial intelligence and real-time imaging navigation in radical gastrectomy.2025World journal of gastroenterologyFree full text
  23. A pilot study on the clinical feasibility of 5G remote robot-assisted gastrectomy.2025World journal of surgical oncologyFree full text
  24. Correlation of the apoptosis in the mitochondrial pathway with the JAK2/STAT3 signaling pathway regarding the effect of Agaricus blazei Murill extract FA-2-b-β in inhibiting the proliferation of gastric cancer cells.2024Asian journal of surgery
  25. Agaricus blazei Murill extract FA-2-b-β inhibits gastric cancer cell proliferation through the mechanisms of cell-cycle blocking and apoptosis by the mitochondrial pathway.2024Asian journal of surgery
  26. Letter to the Editor on "Programmed 'seven-step method' mode in the clinical application of laparoscopic radical resection of distal gastric cancer".2024Asian journal of surgery
  27. Gastric cancer-induced hemophagocytic lymphohistiocytosis: A case report.2024Asian journal of surgery
  28. Extensive gas accumulation in the gastric wall after chemotherapy combined with target-immunotherapy for gastric adenocarcinoma: A case report.2024Asian journal of surgery
  29. Risk factors for gastroparesis syndrome after radical gastric cancer surgery.2024Asian journal of surgery
  30. Perioperative outcomes of da Vinci robot versus laparoscopic-assisted D2 radical resection of distal gastric cancer with Billroth II anastomosis.2024Asian journal of surgery
  31. Construction of a Cuproptosis-Related Gene Signature for Predicting Prognosis in Gastric Cancer.2024Biochemical genetics
  32. Regulatory mechanisms and potential therapeutic targets in precancerous lesions of gastric cancer: A comprehensive review.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.2024Combinatorial chemistry & high throughput screening
  34. The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer.2024Current pharmaceutical biotechnology
  35. YTHDF2 promotes gastric cancer progression and enhances chemoradiotherapy resistance.2024Drug development research
  36. Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer.2024European journal of medical researchFree full text
  37. Network pharmacology and experimental verification: Unraveling Zhiwei Fuwei Pills's role and mechanism in angiogenesis of precancerous lesions of gastric cancer.2024Human & experimental toxicology
  38. Correlation of mir-221-3p differential expression with clinical characteristics of gastric cancer patients.2024Molecular biology reports
  39. MARK4 promotes the malignant phenotype of gastric cancer through the MAPK/ERK signaling pathway.2024Pathology, research and practice
  40. Identification of the whole genome of alternative splicing and RNA-binding proteins involved in nintedanib-induced apoptosis in gastric cancer cells.2024PeerJFree full text
  41. Proteomic study on nintedanib in gastric cancer cells.2024PeerJFree full text
  42. Splenectomy versus splenic preservation in total gastrectomy for gastric cancer: a systematic review and meta-analysis comparing survival benefits and short-term complications.2024Postgraduate medicine
  43. Serum extracellular vesicle-derived miR-21-5p and miR-26a-5p as non-invasive diagnostic potential biomarkers for gastric cancer: A preliminary study.2024The International journal of biological markers
  44. Complete clinical response in neoadjuvant treatment of advanced gastric cancer under multidisciplinary treatment mode.2023Asian journal of surgery
  45. Advances in the application of robotic surgical systems to gastric cancer: A narrative review.2023Asian journal of surgery
  46. The safety and feasibility of spleen pull-out lymph node dissection in total gastrectomy: A systematic review and meta-analysis.2023Asian journal of surgery
  47. Glutamate-cysteine ligase catalytic and its modifier function as novel immunotargets in gastric adenocarcinoma.2023Asian journal of surgery
  48. Quercetin inhibits the proliferative effect of gastric cancer cells by activating the pyroptosis pathway.2023Asian journal of surgery
  49. Isolated foot metastasis after radical surgery for gastric cancer: A case report.2023Asian journal of surgery
  50. The Correlation Between 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Semiquantitative Parameters and the Clinical Features and Pathological Biological Indexes of Gastric Cancer.2023Cancer biotherapy & radiopharmaceuticals
  51. Flavonoid-Rich Extract of Oldenlandia diffusa (Willd.) Roxb. Inhibits Gastric Cancer by Activation of Caspase-Dependent Mitochondrial Apoptosis.2023Chinese journal of integrative medicine
  52. MTF1 has the potential as a diagnostic and prognostic marker for gastric cancer and is associated with good prognosis.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  53. Expression and Clinical Significance of PIEZO2 in Gastric Cancer.2023Combinatorial chemistry & high throughput screening
  54. Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of gastric cancer cells by accelerating TGF-β and enhances chemoradiotherapy resistance.2023Journal of cancer research and clinical oncologyFree full text
  55. Feasibility of Enhanced Recovery After Surgery Protocols Implemented Perioperatively in Endoscopic Submucosal Dissection for Early Gastric Cancer: A Single-Center Retrospective Study.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  56. Extracellular vesicles, hyperadhesive von willebrand factor, and outcomes of gastric cancer: a clinical observational study.2023Medical oncology (Northwood, London, England)
  57. High-Mobility Group Box 1 Overexpression Predicts a Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Gastric Cancer by Activating TLR4/NF-κB Signaling.2023Oncology
  58. Clinical characteristics and prognostic nomogram analysis of patients with dual primary cancers with first gastric cancer: a retrospective study in China.2023PeerJFree full text
  59. PDT for Gastric Cancer - the view from China.2023Photodiagnosis and photodynamic therapy
  60. Safety and Efficacy of Carbon Nanoparticle-Labeled Lymph Node Dissection in Radical Resection of Gastric Cancer: A Systematic Review and Meta-Analysis.2023Technology in cancer research & treatmentFree full text
  61. Prognostic significance of N6-methyladenosine-modified related chemotransferase METTL3 in gastric carcinoma: Evidence from meta-analysis.2023The International journal of biological markers
  62. High expression of the circadian clock gene NPAS2 is associated with progression and poor prognosis of gastric cancer: A single-center study.2023World journal of gastroenterologyFree full text
  63. Expression of Shh, Gli1, and Cyr61 in Gastric Cancer Predicts Overall Survival of Patients: A Retrospective Study.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  64. S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma.2022Chinese medical journalFree full text
  65. The application of enhanced recovery after surgery in minimally invasive gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials.2022Expert review of gastroenterology & hepatology
  66. Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  67. Proximal Gastrectomy Versus Total Gastrectomy for Siewert II/III Adenocarcinoma of the Gastroesophageal Junction: a Systematic Review and Meta-analysis.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  68. High FN1 expression correlates with gastric cancer progression.2022Pathology, research and practice
  69. Targeted metabolomic profiles of serum amino acids and acylcarnitines related to gastric cancer.2022PeerJFree full text
  70. Clinical efficacy and safety of robotic distal gastrectomy for gastric cancer: a systematic review and meta-analysis.2022Surgical endoscopy
  71. Diagnostic values of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in second primary cancers with a gastric primary cancer.2021Asian journal of surgery
  72. Expression and clinical significance of paired- related homeobox 1 and Smad2 in gastric cancer.2021European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  73. A commentary on "Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis" [Int. J. Surg. 73 (2020) 28-41].2021International journal of surgery (London, England)
  74. Contribution of upregulated aminoacyl-tRNA biosynthesis to metabolic dysregulation in gastric cancer.2021Journal of gastroenterology and hepatologyFree full text
  75. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.2021Pathology oncology research : PORFree full text
  76. Relationship of ERCC5 genetic polymorphisms with metastasis and recurrence of gastric cancer.2021Revista da Associacao Medica Brasileira (1992)
Chinese-language papers (not in the count)2
  1. [Zhiwei Fuwei Pills regulate miRNA-21/Bcl-2 pathway to improve mitochondrial apoptosis in rats with precancerous lesions of gastric cancer].2025Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  2. [Primary gastric choriocarcinoma with deletion mutations in the PTEN gene: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06949033Study sitePhase 3Start 2025-05
  3. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06925243Study sitePhase 3Start 2025-04
  4. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  5. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 002025

8 hospitals in Lanzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led7
  1. Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.2024AAPS PharmSciTech
  2. Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets.2024Medicine
  3. Osteosarcoma of the sphenoid bone: A case report.2023Asian journal of surgery
  4. Metacarpal osteosarcoma with chest wall metastasis: A case report.2023Asian journal of surgery
  5. The giant retroperitoneal Extraosseous Ewing's sarcoma: A case report.2022Asian journal of surgery
  6. Cinobufagin inhibits tumor progression and reduces doxorubicin resistance by enhancing FOXO1-mediated transcription of FCGBP in osteosarcoma.2022Journal of ethnopharmacology
  7. Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.2021Technology in cancer research & treatment
Earlier papers (2016–2020)5
  1. [Application of apparent diffusion coefficient combined with serum tumor markers detection in evaluating neoadjuvant chemotherapy for osteosarcoma].2020Zhonghua yi xue za zhi
  2. Construction of microRNA-messenger networks for human osteosarcoma.2019Journal of cellular physiology
  3. miR-20a-enhanced cell migration and invasion via ATg5 in osteosarcoma.2019Minerva endocrinologica
  4. miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.2019Yonsei medical journal
  5. Computer-aided discovery and biological characterization of human lactate dehydrogenase 5 inhibitors with anti-osteosarcoma activity.2018Bioorganic & medicinal chemistry letters

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Lanzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

3 hospitals in Lanzhou for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersMedical oncology
Papers it led3
  1. Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy.2024Obesity surgery
  2. LncRNA RP11-1100L3.8 Involves in the Pathogenesis of Multiple Myeloma by Regulating NR4A1.2023Discovery medicine
  3. miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3.2023Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)7
  1. [The Significance of Bone Marrow Plasma Cell Percentage and Immature Plasma Cells in the Prognosis of Newly Diagnosed Multiple Myeloma Patients].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  3. [Effects of Different Nutritional Scoring Systems on Prognosis of Elderly Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  4. [Coagulation Indexes and Their Prognostic Significance in Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  5. [The Influence of Serum Homocysteine Level to the Prognosis of Newly Diagnosed Multiple Myeloma Patients and Analysis of Related Factors].2021Zhongguo shi yan xue ye xue za zhi
  6. [Analysis on Related Factors of Pulmonary Infection in Patients with Multiple Myeloma Treated with Bortezomib].2021Zhongguo shi yan xue ye xue za zhi
  7. [Value of Neutrophil/Lymphocyte Ratio and Monocyte/Lymphocyte Ratio in the Prognosis of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Lanzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLymphoma & cancer-related HLH
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Lanzhou for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Lanzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Tibiotalocalcaneal arthrodesis for the treatment of ankle joint Charcot disease:a case report].2022Zhongguo gu shang = China journal of orthopaedics and traumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Morgagni's Hernia and Duodenal Stenosis Found to Co-Exist in Children with Down's Syndrome: A Case Report.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Lanzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

甘肃省人民医院

Gansu Provincial Hospital

兰州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Gansu Provincial People's Hospital; Gansu Provincial Hospital of Traditional Chinese Medicine; Gansu Provincial Hospital of TCM; Gansu University of Chinese Medicine (Gansu Provincial Hospital)

Suggest a correctionDownload the data